Close X
Attorney Spotlight

What colorful method does Claire Miley use to keep up with the latest healthcare regulations as they relate to proposed transactions? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

CLARCOR
Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Securities Law Exchange BlogSecurities Law Exchange blog offers insight on the latest legal and regulatory developments affecting publicly traded companies. It focuses on a wide variety of topics including regulation and reporting updates, public company advisory topics, IPO readiness and exchange updates including IPO announcements, M&A trends and deal news.

Read More >

Brian Roark on Medicare Billing Fraud for Healthcare Risk Management

Media Mentions

January 25, 2010

Brian Roark, attorney at Bass, Berry & Sims, is extensively quoted regarding Medicare billing fraud for Healthcare Risk Management. The article, titled "Avoid Being Drawn Into Billing Fraud," discussing seven recent cases of fraudulent Medicare billing totaling $26 million in unneeded or undelivered medical equipment, was published on January 1, 2010.

From the article:

Such brazen fraud likely would not go unnoticed by a risk manager if it originated within the organization, but it still is possible to get involved in these schemes unless you take the right precautions, says Brian D. Roark, JD, an attorney with the law firm of Bass, Berry and Sims in Nashville, TN.

"On the criminal side, the federal government is devoting significant resources to prosecuting street-level fraud cases where Medicare or Medicaid is billed for services not rendered, such as individuals setting up fake medical supply companies," he says. "Additionally, the government is employing increasingly sophisticated investigative techniques to spot fraud, such as using data mining to find aberrations in claims-filing patterns and using prepayment claims editing to compare new claims to previous claims and detect fraud in almost real time. Some of the primary areas of focus by the government are on durable medical equipment [DME], prosthetics, orthotics and supplies, home health agencies, and infusion therapy."

Roark also points out that the Fraud Enforcement and Recovery Act of 2009 (FERA) made significant amendments to the False Claims Act (FCA), which is the primary civil enforcement tool for health care fraud. The result of the FERA amendments was to expand liability under the FCA, take away certain defenses previously available to defendants, make it easier for the government to share information with qui tam whistle-blower plaintiffs, and expand whistle-blower protections.

"The FERA amendments likely will increase the number of FCA lawsuits brought against health care providers," Roark says.

Roark says a key way to avoid involvement in such fraud is to make compliance the responsibility of the entire organization and provide mechanisms for employees to raise any compliance concerns.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.